New anti-obesity pills threaten Eli Lilly and Novo Nordisk’s stock market empire
As more pharmaceutical companies make inroads in the weight loss market, the two firms saw their shares fall more than 10% in the last month
As more pharmaceutical companies make inroads in the weight loss market, the two firms saw their shares fall more than 10% in the last month
Around the world, 100 companies have debuted weight-loss medications, which have become a multimillion-dollar business. Novo Nordisk’s Ozempic is currently the best-known, but it’s far from the only option
The semaglutide craze is a global phenomenon, but among its unwanted side effects is a premature aging of the face. Health professionals have found themselves administering anti-aging treatments to an ever-younger clientele
Citi estimates that the fight against obesity will generate revenue of $158 billion in 2035. The main risk for the sector is the difficulty in guaranteeing supply
The economic impact of obesity will reach losses of up to $4 trillion by 20235, or 3% of global GDP
During trials, patients showed reduced appetite and even an aversion towards food generally. This has the potential to affect giant companies such as Nestlé and Cadbury
The drugs include the blood thinner Eliquis, diabetes treatment Jardiance and eight other medications
Patients given monthly infusions of Eli Lilly and Co.’s donanemab declined about four to seven months more slowly than those given dummy infusions in a large study
The Danish drugmaker said Tuesday that pre-filled pens and vials of long- and short-acting insulins will see list price reductions
The pharmaceutical company will also immediately expand a cap on costs insured patients pay to fill prescriptions